Categories Earnings

CarMax tumbles after Q4 results miss estimates; Plans aggressive store expansion

Shares of CarMax (KMX) nosedived Wednesday after the used car retailer reported fourth-quarter earnings and revenues that missed analysts’ expectations. While the downtrend in the used vehicle division continues to drag the top line, the company announced plans to add more stores next year and beyond.

Fourth-quarter profit sagged 17% annually to $0.67 per share, contrary to expectations for an increase. The bottom-line was negatively impacted by a one-time charge related to the recent income tax reform.

Net sales and operating revenues increased modestly to $4.1 billion as a marked growth in wholesale unit sales more than compensated a decline in used unit sales. However, total revenues came in below Street forecast.

CarMax earnings decline on tax charges

Comparable store sales in the used vehicle unit dropped 8% in the recently ended quarter hurt by softer traffic and relatively flat conversion, besides seasonal factors. Of late, the used car division has been feeling the heat from the cost escalation triggered by higher interest rates and too many off-lease cars hitting the market.

“We’re disappointed in our fourth quarter comparable store unit sales performance, which we believe was partly affected by macro pricing factors resulting in a softer sales environment,” said CarMax CEO Bill Nash.

The company, which operates in the Car Sales and Auto Finance segments, opened four new stores during the fourth quarter. As part of expanding the store presence, 15 new stores will be opened next year and 13-16 stores in fiscal 2020.

Comparable store sales were hit by softer traffic and relatively flat conversion

The company also repurchased 1.9 million shares for $127.8 million. It is expected that higher investments in infrastructure would push up capital expenditures to about $340 million in fiscal 2019.

Among CarMax’s competitors, AutoNation (AN) is scheduled to announce financial results for its more recent quarter on May 3.

CarMax shares fell more than 3% when the market opened today, denting expectations for an increase. A potential depletion in market value would add to the woes of CarMax which recently got embroiled in a series of lawsuits over the safety of the vehicles it sold.

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top